A Lipid-Particle Lens on Insulin Sensitivity
Cardio IQ Insulin Resistance blood testing is a cardiometabolic panel that estimates how resistant your body is to insulin (insulin resistance). It measures insulin produced by pancreatic beta cells alongside select metabolic signals released into the bloodstream by the liver, fat tissue, and circulating lipoproteins, then brings them together into a coherent picture of insulin action. In plain terms, it reads the chemical fingerprints that show how hard insulin must work to keep your energy fuels in balance (pancreatic insulin secretion, hepatic glucose handling, fat metabolism).
Insulin's job is to move glucose into muscle and fat and to tell the liver and fat cells to shift from releasing fuels to storing them (glucose uptake, suppression of hepatic glucose output and lipolysis). When tissues respond poorly, the pancreas compensates by raising insulin, lipid patterns shift, and metabolic strain builds. This test captures that physiology, offering a snapshot of whole‑body insulin signaling efficiency and its downstream effects—an early view of cardiometabolic stress that can emerge before obvious sugar abnormalities appear (dysglycemia).
Catching Cardiometabolic Strain Before Glucose Rises
The Cardio IQ Insulin Resistance blood test estimates how effectively your body responds to insulin—the hormone that moves glucose into muscle and liver cells. It reveals metabolic stress long before blood sugar rises, linking everyday energy, appetite signals, liver fat handling, blood pressure tone, and cholesterol particle patterns to future risks for diabetes and heart disease. Because insulin orchestrates how cells use and store energy, this score reflects the efficiency of glucose handling, liver fat export, and lipid trafficking. It links directly to whole‑body metabolism, cardiovascular risk, liver health, reproductive hormones, and brain energy balance.
Reading a Cardio IQ Insulin Resistance Score
Reference ranges vary by lab, but lower scores or indices generally indicate better insulin sensitivity; within reference ranges tends to sit toward the low end. When values are low, tissues are receptive to insulin, glucose transitions smoothly into cells, and the pancreas doesn't need to overwork. People often experience steady energy, fewer post‑meal crashes, and easier weight control. Younger individuals and premenopausal women often show lower scores. Early pregnancy can be lower, with a natural rise later. Rarely, a low result paired with high glucose can mean inadequate insulin production (beta‑cell failure), which is interpreted in context with glucose and A1c.
Being in range suggests stable insulin signaling, flexible fuel use, and balanced lipoprotein metabolism, which supports steady energy, healthier vascular function, and lower long‑term cardiometabolic risk. For most populations, optimal cardiovascular risk tracks toward the lower end of the reference range.
Higher values reflect insulin resistance: cells ignore insulin signals, prompting the pancreas to produce more. This hyperinsulinemia drives higher triglycerides, lower HDL, smaller denser LDL particles, rising blood pressure, and liver fat accumulation. The liver increases production of triglyceride‑rich VLDL; LDL and HDL particles shift toward smaller, denser forms. Common life effects include fatigue after carbohydrate‑rich meals, increased waist size, cravings, skin tags, and darkened neck/underarm skin. In women it can disrupt ovulation and suggest risk for polycystic ovary syndrome; in men it associates with lower testosterone and erectile issues. Children and teens may show resistance during puberty, amplified by excess weight. In pregnancy, elevated resistance signals higher risk for gestational diabetes and hypertensive disorders.
What Can Shift a Cardio IQ Insulin Resistance Score
Notes: This score is derived from lipoprotein measurements and is typically interpreted alongside glucose, A1c, insulin, and triglycerides. Fasting, acute illness, pregnancy, puberty, and medications (for example glucocorticoids and some antipsychotics) can shift results. Scores often rise with aging, after menopause, in puberty, in polycystic ovary syndrome, and in late pregnancy. Assay methods and reference ranges vary by lab.
Where Insulin Resistance Sits in the Bigger Picture
Big picture: insulin resistance sits at the crossroads of metabolism, vascular health, liver function, and reproduction. Interpreted alongside fasting glucose, A1c, triglycerides, HDL, liver enzymes, and waist measures, this test helps map long‑term risk for type 2 diabetes, fatty liver disease, and atherosclerotic cardiovascular events.
FAQs
Cardio IQ Insulin Resistance is a calculated score derived from a blood sample that estimates how resistant your body’s cells are to insulin. It uses patterns in advanced cardiometabolic markers—such as glucose, triglycerides, and lipoprotein profiles—to assess how effectively insulin moves glucose into cells and manages fat metabolism. The score reflects the integrated activity of insulin across key tissues like the liver, muscle, and fat, providing a single readout of your insulin signaling status. Lower scores indicate better insulin sensitivity, while higher scores suggest insulin resistance, which is linked to increased risk for diabetes, heart disease, and metabolic disorders.
Cardio IQ Insulin Resistance can spot early metabolic imbalance before traditional markers like fasting glucose or hemoglobin A1c indicate diabetes or prediabetes. By analyzing subtle shifts in blood lipids and other cardiometabolic markers, it provides an early warning of insulin resistance. This allows for earlier intervention to is studied for its potential effects on progression to diabetes, heart disease, or other complications, making it a valuable tool for proactive health management.
Knowing your Cardio IQ Insulin Resistance score helps clarify the underlying causes of symptoms like fatigue, cravings, weight gain, and high triglycerides. It guides personalized lifestyle and medication choices to improve insulin sensitivity and overall metabolic health. The score also supports fertility and PCOS management, pregnancy planning, and tracking progress over time to objectively confirm the benefits of interventions.
Cardio IQ Insulin Resistance is unique because it uses advanced lipid and cardiometabolic markers to estimate insulin sensitivity, rather than relying solely on glucose or insulin levels. Unlike other indices, it captures the integrated effects of insulin on glucose and fat metabolism across multiple organ systems. It is not interchangeable with other insulin resistance tests, as different labs use different algorithms and markers.
High Cardio IQ Insulin Resistance scores are associated with symptoms such as post-meal sleepiness, brain fog, cravings, central weight gain, elevated triglycerides, lower HDL, higher blood pressure, and liver fat. In women, high scores may indicate menstrual irregularity or features of polycystic ovary syndrome (PCOS). During pregnancy, elevated scores signal a higher risk for gestational diabetes. Persistently high values in children and teens are linked to future cardiometabolic risk.
Superpower currently offers at-home blood testing in the following states: Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Kansas, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, and Wisconsin.
We’re actively expanding nationwide, with new states being added regularly. If your state isn’t listed yet, stay tuned.
References
- Freeman, A. M., Acevedo, L. A., & Pennings, N. (2023). Insulin resistance. In StatPearls. StatPearls Publishing. https://pubmed.ncbi.nlm.nih.gov/29939616/
- Sanchez-Garcia, A., Rodriguez-Gutierrez, R., Mancillas-Adame, L., Gonzalez-Nava, V., Diaz Gonzalez-Colmenero, A., Solis, R. C., Alvarez-Villalobos, N. A., & Gonzalez-Gonzalez, J. G. (2020). Diagnostic accuracy of the triglyceride and glucose index for insulin resistance: A systematic review. International Journal of Endocrinology, 2020, 4678526. https://doi.org/10.1155/2020/4678526
- Tahapary, D. L., Pratisthita, L. B., Fitri, N. A., Marcella, C., Wafa, S., Kurniawan, F., Rizka, A., Tarigan, T. J. E., Harbuwono, D. S., Purnamasari, D., & Soewondo, P. (2022). Challenges in the diagnosis of insulin resistance: Focusing on the role of HOMA-IR and Tryglyceride/glucose index. Diabetes & Metabolic Syndrome, 16(8), 102581. https://doi.org/10.1016/j.dsx.2022.102581
- Hantzidiamantis, P. J., Awosika, A. O., & Lappin, S. L. (2024). Physiology, glucose. In StatPearls. StatPearls Publishing. https://pubmed.ncbi.nlm.nih.gov/31424785/
- American Diabetes Association Professional Practice Committee. (2024). 2. Diagnosis and classification of diabetes: Standards of care in diabetes-2024. Diabetes Care, 47(Suppl. 1), S20-S42. https://doi.org/10.2337/dc24-S002






































.avif)
